69 results about "Wasting Diseases" patented technology

This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, muscle wasting diseases and / or disorders, bone-related diseases and / or disorders, diabetes, cardiovascular disease, renal disease and others.

The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof.

This invention provides SARM compounds and their use in treating a variety of diseases or conditions in a subject, including, inter-alia, a muscle wasting disease and / or disorder or a bone-related disease and / or disorder.

This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and / or disorder or a bone-related disease and / or disorder.

This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, a muscle wasting disease and / or disorder or a bone-related disease and / or disorder.

This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and / or disorder or a bone-related disease and / or disorder.

The present invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's core body temperature, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ophthalmic condition, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof. The Purine Derivatives include compounds of the following formula:or a pharmaceutically acceptable salt thereofwhereinA is —CH2OHB and C are —OH:D isA and B are trans with respect to each other:B and C are cis with respect to each other:C and D are cis or trans with respect to each other:R1 is —H, -halo, —CN, —N(R2)2, —OR2, —SR2, —NHC(O)R2, —NHC(O)N(R2)2, —NHC(O)OR2, —C(O)OR2, —C(O)R2, —C(O)N(R2)2, —OC(O)N(R2)2, —C(halo)3, or —NO2;each R2 is independently —H, —C1-C10 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —(CH2)n-aryl, —(CH2)n-(3- to 7-membered monocyclic heterocycle, —(CH2)n-(8- to 12-membered bicyclic heterocycle), —(CH2)n—(C3-C8 monocyclic cycloalkyl), —(CH2)n—(C3-C8 monocyclic cycloalkenyl), —(CH2)n—(C8-C12 bicyclic cycloalkyl), or —(CH2)n—(C8-C12 bicyclic cycloalkenyl);each n is an integer ranging from 0 to 6;each p is an integer ranging from 1 to 6; andeach q is an integer ranging from 1 to 6.

The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.